Dyne Therapeutics Inc [DYN] stock is trading at $18.0, down -0.44%. An important factor to consider is whether the stock is rising or falling in short-term value. The DYN shares have gain 9.62% over the last week, with a monthly amount drifted -13.38%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Dyne Therapeutics Inc [NASDAQ: DYN] stock has seen the most recent analyst activity on December 10, 2025, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $40 for it. Previously, Oppenheimer downgraded its rating to Perform on October 10, 2025. On August 25, 2025, upgrade upgraded it’s rating to Strong Buy but maintained its price target of $35 on the stock. Bernstein started tracking the stock assigning a Mkt Perform rating and suggested a price target of $13 on June 24, 2025. In a note dated May 29, 2025, Evercore ISI initiated an Outperform rating and provided a target price of $46 on this stock.
Dyne Therapeutics Inc [DYN] stock has fluctuated between $6.36 and $25.00 over the past year. Currently, Wall Street analysts expect the stock to reach $37.89 within the next 12 months. Dyne Therapeutics Inc [NASDAQ: DYN] shares were valued at $18.0 at the most recent close of the market. An investor can expect a potential return of 110.5% based on the average DYN price forecast.
Analyzing the DYN fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.49, Equity is -0.66 and Total Capital is -0.56. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Dyne Therapeutics Inc’s Current Ratio is 13.47. On the other hand, the Quick Ratio is 13.47, and the Cash Ratio is 9.58.
Transactions by insiders
Recent insider trading involved Kerr Douglas, Officer, that happened on Dec 05 ’25 when 880.0 shares were purchased. Officer, Cox John completed a deal on Dec 05 ’25 to buy 2662.0 shares. Meanwhile, CEO & President Cox John sold 2662.0 shares on Dec 05 ’25.
